Skip to main content
editor@jprims.in
9343055451
e-ISSN: 3049-1681
Journal of Pharmaceutical Research and Integrated Medical Sciences

Journal of Pharmaceutical Research and Integrated Medical Sciences

Journal of Pharmaceutical
Research and Integrated Medical Sciences

Advancing knowledge through rigorous peer-reviewed research across multiple disciplines. Join the global community of scholars shaping the future of academic discovery.

📢 Latest Update: New special issue call for papers on "Pharmaceutical Research and Integrated Medical Sciences" - Submit by September 30, 2026

📢 Latest Update: New special issue call for papers on "Pharmaceutical Research and Integrated Medical Sciences" - Submit by September 30, 2026

Important Journal Details

Title:
Journal of Pharmaceutical Research and Integrated Medical Sciences
Journal Short Name:
JPRIMS
e-ISSN (Online):
3049-1681
Year of Establishment:
2024
Frequency of the Publication:
Monthly (1 Issue / month)
Publication Format:
Online
Scope:
International
Publication URL:
https://jprims.in
Related Subject:
Multi-DisciplinaryMedical Sciences
Language:
English
Editor-in-Chief:
Dr. Arpan Kumar Tripathi
Editorial Board:
Click Here →
Journal's Email ID:
editor@jprims.in

Download Forms & Formats

Download Hub

Publisher Details

Responsible Person Name:
Dr. Arpan Kumar Tripathi
Name of Publishing body:
AKT Publication
Publisher Website Url:
https://www.aktpublication.com
Address:
H-103, Nandi Parishar, Padmanabhpur, Durg, Chhattisgarh-491001

Journal Features

Rigorous Peer Review

All submissions undergo thorough evaluation by experts in the field to ensure quality and validity.

Global Reach

Published papers reach an international audience of researchers, academics, and industry professionals.

Rapid Publication

Efficient review process ensures timely publication of accepted papers without compromising quality.

Open Access

All published papers are freely accessible online, maximizing visibility and impact of your research.

Publication Procedure

1

Prepare Manuscript

Format your paper according to our guidelines

View Guidelines
style="fill: var(--journal-600);"
2

Submit Paper

Upload your manuscript through our system

Submit Now
3

Peer Review

Your paper undergoes expert evaluation

Learn More
4

Publication

Accepted papers are published worldwide

View Publications
View All Issues
Cover image for In Vitro Antioxidant and Antibacterial Evaluation of Optimized Dragon Fruit and Kiwi Fruit Herbal Syrup

In Vitro Antioxidant and Antibacterial Evaluation of Optimized Dragon Fruit and Kiwi Fruit Herbal Syrup

Ketan Shantilal Rathod, Jignesh Modi, Ravikumar R. Patel, Kalubha Shivubha Zala, Zalak Bhupendrakumar Patel, Rakeshkumar Pravinbhai Patel, Jahanviben Chandrakant Patel, Anuviral Patel

Background: Fruit peels are sources of phytoconstituents including polyphenols and flavonoids. Dragon fruit and kiwi fruit peel extracts were incorporated into an optimized herbal syrup to utilize their biological potential. Objective: The study evaluated the in vitro antioxidant and antibacterial activities of an optimized syrup containing ethanolic and aqueous peel extracts of dragon fruit and kiwi fruit. Methods: The optimized syrup contained a total peel-extract load of 5.0% w/v. Antioxidant activity was evaluated using the DPPH radical-scavenging assay at syrup concentrations of 10-50 mg/mL, with ascorbic acid at 20-100 µg/mL as standard. Antibacterial activity was evaluated by agar well diffusion against Staphylococcus aureus and Escherichia coli using ciprofloxacin (5 µg/mL) as positive standard. Results: DPPH scavenging increased from 22.56% at 10 mg/mL to 85.51% at 50 mg/mL. The calculated IC50 values were 25.18 mg/mL for the syrup and 37.92 µg/mL for ascorbic acid. The syrup produced zones of inhibition of 22.4 ± 0.5 mm against S. aureus and 18.6 ± 0.8 mm against E. coli. Net zones were 16.4 and 12.6 mm, and relative antibacterial efficacies were 73.87% and 61.46%, respectively. Conclusion: The optimized formulation demonstrated concentration-dependent DPPH radical-scavenging activity and antibacterial activity against both test organisms, with greater antibacterial activity against S. aureus.

Cover image for Traumatic Direct Carotid-Cavernous Fistula Presenting with Delayed Epistaxis and Visual Loss Managed by Parent Artery Occlusion: A Case Report

Traumatic Direct Carotid-Cavernous Fistula Presenting with Delayed Epistaxis and Visual Loss Managed by Parent Artery Occlusion: A Case Report

Ugandar R.E, Arshiya Nousheen K, Glory Esther Rani M, Triveni B, Sai Priyanka D

Background: A high-flow arteriovenous connection between the internal carotid artery (ICA) and the cavernous sinus is known as a direct carotid-cavernous fistula (CCF). The most common cause of direct CCF is trauma, and the current standard of care is endovascular therapy. Visual impairment and severe epistaxis are rare but dangerous presentations that may require immediate, effective treatment. Case: About a month after a fall from a height that resulted in right-eye blindness, a 29-year-old man developed acute nasal bleeding after sneezing. A direct right CCF was confirmed by digital subtraction angiography (DSA), which showed a significant rent between the right cavernous ICA and cavernous sinus with no distal flow into the right anterior and middle cerebral arteries. Deconstructive right ICA parent artery blockage with coils was used to treat the fistula as there was no distal right ICA flow and collateral cerebral circulation. Complete right ICA occlusion, no residual CCF, and collateral supply to the right hemisphere via the anterior and posterior communication channels were all shown by follow-up angiography. Conclusion: In conclusion, this case demonstrates delayed post-traumatic direct CCF that mostly manifests as epistaxis and visual loss instead of the traditional ocular triad. When reconstructive preservation of the wounded ICA was not possible, angiographic evaluation of collateral circulation was essential to safely choosing parent artery closure.

Cover image for Development and DoE-Based Optimization of Dragon Fruit and Kiwi Fruit Herbal Syrup: Formulation, Physicochemical Characterization and Stability Evaluation

Development and DoE-Based Optimization of Dragon Fruit and Kiwi Fruit Herbal Syrup: Formulation, Physicochemical Characterization and Stability Evaluation

Ketan Shantilal Rathod, Jignesh Modi, Ravikumar R. Patel, Kalubha Shivubha Zala, Zalak Bhupendrakumar Patel, Rakeshkumar Pravinbhai Patel, Jahanviben Chandrakant Patel, Anu viral Patel

Background: Herbal syrups provide a convenient oral dosage form for incorporation of plant-derived constituents, but suspended herbal extracts may present challenges related to viscosity, sedimentation and physical stability. Objective: The study aimed to develop and optimize a herbal syrup containing dragon fruit and kiwi fruit peel extracts using a Design of Experiments approach and to characterize the optimized formulation for physicochemical properties and accelerated stability. Methods: Ethanolic and aqueous peel extracts of dragon fruit and kiwi fruit were incorporated into a sucrose-based syrup containing sodium carboxymethyl cellulose (Na-CMC). A two-factor, five-level Central Composite Design consisting of 13 experimental runs was used. Na-CMC concentration (0.16-0.44%) and sucrose concentration (34.4-72.6%) were independent variables, while viscosity and sedimentation were dependent responses. Quadratic models were evaluated by analysis of variance and numerical optimization. Results: The viscosity model was significant (F=29.59, p=0.0001, R²=0.9548) and the sedimentation model was significant (F=14.64, p=0.0014, R²=0.9127). Numerical optimization identified 0.318971% Na-CMC and 66.6245% sucrose, with desirability 1.000. Predicted viscosity and sedimentation were 364.22 cP and 0.0976969%, respectively. Experimental validation gave 368.45 cP viscosity and 0.10% sedimentation. Conclusion: The CCD-based approach identified an optimized herbal syrup containing approximately 0.32% Na-CMC and 66.62% sucrose with acceptable viscosity and minimal sedimentation. The formulation was selected for accelerated stability assessment at 40±2°C/75±5% RH for six months.

Publication Procedure

Learn about our 4-step publication process

Author Guidelines

Review requirements before submitting

Submit Article

Ready to submit your research?

165
Published Articles
1,523
Active Researchers
195
Countries
4.2
Impact Factor